CLINICAL TRIALS PROFILE FOR DESOXYN
✉ Email this page to a colleague
All Clinical Trials for DESOXYN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01967381 ↗ | Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse | Completed | National Institute on Drug Abuse (NIDA) | Early Phase 1 | 2013-10-01 | The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of combined oxazepam and naltrexone for managing methamphetamine dependence. |
NCT01967381 ↗ | Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse | Completed | University of Kentucky | Early Phase 1 | 2013-10-01 | The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of combined oxazepam and naltrexone for managing methamphetamine dependence. |
NCT02058966 ↗ | Pilot Study of Entacapone for Methamphetamine Abuse | Completed | Portland VA Medical Center | Early Phase 1 | 2014-06-01 | Addiction to methamphetamine is a serious health problem. There are no medications that a doctor can give someone to help them stop using methamphetamine. Entacapone (Comtan©) is a medication that could help people addicted to methamphetamine. This study will see how entacapone works in healthy people who are given methamphetamine. We think that the study drug will be well tolerated, and that it will prevent some of the effects of methamphetamine that make it so addictive. We also want to see how differences in people's genes may cause differences in the ways the study drug and methamphetamine work for them. The study has six total visits. The first visit is for screening. Tests and procedures will make sure it is safe for subjects to participate. The second visit is a familiarization day. Subjects will receive methamphetamine, but no entacapone. This is done to make sure they can tolerate the drug and recognize its effects before being given a second drug on the same day. Subjects will take surveys and computer tests to see how the medications change mood, thinking, and liking the drug. The final four visits are the actual study days. Subjects will be randomly assigned (like the flip of a coin) to the different ways to get either 1) study medication or placebo (placebo contains no active study medication) and then 2) methamphetamine or placebo. Subjects will be in all four groups during the study, which means that each day a subject will get a different group. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DESOXYN
Condition Name
Clinical Trial Locations for DESOXYN
Trials by Country
Clinical Trial Progress for DESOXYN
Clinical Trial Phase
Clinical Trial Sponsors for DESOXYN
Sponsor Name